Ras mutations are frequent in lung and pancreatic cancers, but in several mouse models of these cancers, oncogenic Ras activity requires EGFR activation and tumor growth is reduced by EGFR ablation (Ardito et al., 2012; Kruspig et al., 2018; Moll et al., 2018; Ponsioen et al., 2021). The gene discussed is EGFR; the disease is cancer.